Scholarlink

<p>Non-Hodgkin lymphomas (NHLs) are among the most common cancers in the US, yet their etiology is mostly unknown. Epstein-Barr virus (EBV) is a known driver of rare NHLs, but its role in common subtypes is unclear. We evaluated associations between antibodies to 16 EBV antigens, including 12 emerging markers (anti-: BARF1, BBRF1, BFRF1, BGLF2, BHRF1, BORF1, BPLF1, BRLF1, BXLF1, LF2, LMP1, VCAp40) and NHL risk in prediagnostic blood samples from 2134 case-control sets from 4 prospective cohort studies. Conditional logistic regression estimated odds ratios (ORs) and 95% confidence intervals (CIs). Associations across multiple antibodies were summarized using a β‑weighted score (EBVAb score). Eight markers were positively associated with NHL risk. Anti-LMP1 was associated with diffuse large B-cell lymphoma (DLBCL; OR = 2.83, 95% CI: 1.12–7.19) only. Six lytic markers (anti-: BGLF2, VCAp40, BFRF1, BARF1, BHRF1, BXLF1) were associated with a 2–3 times higher risk of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Lytic marker associations for DLBCL and follicular lymphoma (FL) were weaker, with exceptions: anti-BXLF1 and DLBCL: OR = 2.25, 95% CI: 1.33–3.81; anti-BHRF1 and FL: OR = 2.75, 95% CI: 1.22–6.18. Anti-EBV scores &gt; 0 were associated with ~50% higher NHL risk, strongest for CLL/SLL (Tertile 3: OR = 2.43, 95% CI: 1.30–4.55). Select EBV antibodies may serve as markers of common NHL risk.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma: a pooled analysis of four prospective cohorts

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月16日

查看全文
  • Lauren R. Teras,
  • Mariah Landry,
  • James M. Hodge,
  • Parichoy Pal Choudhury,
  • Brenda M. Birmann,
  • Wendy Cozen,
  • Jonathan N. Hofmann,
  • Rima Jeske,
  • Mark P. Purdue,
  • James R. Cerhan,
  • Loïc Le Marchand,
  • Aisha Babi,
  • Alpa V. Patel,
  • Tim Waterboer

摘要

Non-Hodgkin lymphomas (NHLs) are among the most common cancers in the US, yet their etiology is mostly unknown. Epstein-Barr virus (EBV) is a known driver of rare NHLs, but its role in common subtypes is unclear. We evaluated associations between antibodies to 16 EBV antigens, including 12 emerging markers (anti-: BARF1, BBRF1, BFRF1, BGLF2, BHRF1, BORF1, BPLF1, BRLF1, BXLF1, LF2, LMP1, VCAp40) and NHL risk in prediagnostic blood samples from 2134 case-control sets from 4 prospective cohort studies. Conditional logistic regression estimated odds ratios (ORs) and 95% confidence intervals (CIs). Associations across multiple antibodies were summarized using a β‑weighted score (EBVAb score). Eight markers were positively associated with NHL risk. Anti-LMP1 was associated with diffuse large B-cell lymphoma (DLBCL; OR = 2.83, 95% CI: 1.12–7.19) only. Six lytic markers (anti-: BGLF2, VCAp40, BFRF1, BARF1, BHRF1, BXLF1) were associated with a 2–3 times higher risk of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Lytic marker associations for DLBCL and follicular lymphoma (FL) were weaker, with exceptions: anti-BXLF1 and DLBCL: OR = 2.25, 95% CI: 1.33–3.81; anti-BHRF1 and FL: OR = 2.75, 95% CI: 1.22–6.18. Anti-EBV scores > 0 were associated with ~50% higher NHL risk, strongest for CLL/SLL (Tertile 3: OR = 2.43, 95% CI: 1.30–4.55). Select EBV antibodies may serve as markers of common NHL risk.